OMIGAPIL MALEATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H17NO.C4H4O4
Molecular Weight	391.4165
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C13

InChI

InChIKey=SQAZQLMBEHYFJA-BTJKTKAUSA-N

InChI=1S/C19H17NO.C4H4O4/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19;5-3(6)1-2-4(7)8/h1,4-11,13H,12,14H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula	C19H17NO
Molecular Weight	275.3444
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9488718 | https://www.ncbi.nlm.nih.gov/pubmed/16505364 | https://www.ncbi.nlm.nih.gov/pubmed/17709710 | https://www.ncbi.nlm.nih.gov/pubmed/17110281 | http://www.santhera.com/health-care-professionals/our-pipeline/cmd

Omigapil (CGP 3466 or TCH346) is a structurally related analog of R-(-)-deprenyl that exhibits virtually no monoamine oxidase type B inhibiting activity but is neuroprotective in the picomolar concentration range. It binds to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and at subnanomolar concentrations prevent the S-nitrosylation of GAPDH, inhibit GAPDH-Siah binding and prevent the nuclear translocation of GAPDH. Omigapil demonstrated promising potential in the treatment of Parkinson's disease and motoneuron disease in animal models, however, it did not show efficacy in clinical trials. Omigapil is in development for the treatment of congenital muscular dystrophy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glyceraldehyde-3-phosphate dehydrogenase liver 2 Target ID: CHEMBL2284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16510976 \| https://www.ncbi.nlm.nih.gov/pubmed/16505364 \| https://www.ncbi.nlm.nih.gov/pubmed/9488718	Binding Agent 1076
apoptotic process 51 Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9488718	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Congenital muscular dystrophy 2 Sources: http://www.santhera.com/health-care-professionals/our-pipeline/cmd	Primary	Phase I 438	Unknown Approved Use Unknown
Parkinson's disease 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17110281	Primary	Phase II 1147	Unknown Approved Use Unknown
Amyotrophic lateral sclerosis 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17709710	Primary	Phase III 665	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
15 mg 1 times / day multiple, oral Highest studied dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17709710	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17709710	Sources: https://pubmed.ncbi.nlm.nih.gov/17709710
10 mg 1 times / day multiple, oral Studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17110281	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17110281	Sources: https://pubmed.ncbi.nlm.nih.gov/17110281

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00C4YO	https://www.1pchem.com/search?query=1P00C4YO
AK Scientific	X3610	https://aksci.com/item_detail.php?cat=X3610
ApexBio Technology	B5354	https://www.apexbt.com/catalogsearch/result/?q=B5354
BOC Sciences	200189-97-5	http://www.bocsci.com/description.asp?cas=200189-97-5
eMolecules	28326214	https://orderbb.emolecules.com/search/#?query=28326214
eMolecules	32275638	https://orderbb.emolecules.com/search/#?query=32275638
eMolecules	45920010	https://orderbb.emolecules.com/search/#?query=45920010
MolPort	MolPort-023-276-617	https://www.molport.com/shop/molecule-link/MolPort-023-276-617
MuseChem	M136998	https://www.musechem.com/product/M136998.html
MuseChem	R028763	https://www.musechem.com/product/R028763.html
ShangHai Biochempartner	BCP24057	http://www.biochempartner.com/search_BCP24057
Tocris	2966	https://www.tocris.com/search.php?Type=QuickSearch&Value=2966
Toronto Research Chemicals	C427813	https://www.trc-canada.com/product-detail/?CatNum=C427813
Toronto Research Chemicals	O640000	https://www.trc-canada.com/product-detail/?CatNum=O640000

PubMed

Title	Date	PubMed
Targets for neuroprotection in Parkinson's disease.	2009-07	18930814
Phase II/III randomized trial of TCH346 in patients with ALS.	2007-08-21	17709710
Post-translational protein modifications in type 1 diabetes: a role for the repair enzyme protein-L-isoaspartate (D-aspartate) O-methyltransferase?	2007-03	17216280
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.	2006-12	17110281
High-resolution structure of human D-glyceraldehyde-3-phosphate dehydrogenase.	2006-03	16510976
The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.	2006-02-24	16242883
CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice.	2004-12	15799550
Clinical trials of neuroprotection for Parkinson's disease.	2004-10-12	15477583
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.	2004-10-12	15477581
Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.	2004-06	15204010
Simultaneous analytical method for the determination of TCH346 and its four metabolites in human plasma by liquid chromatography/tandem mass spectrometry.	2004	14966843
CGP 3466 increases survival of cultured fetal dopaminergic neurons.	2003	12808200

Patents

Sample Use Guides

In Vivo Use Guide

Phase II/III randomized trial of TCH346 in patients with ALS: Patients were randomly assigned in a double-blind fashion to receive either placebo or one of four doses of TCH346 (1.0, 2.5, 7.5, or 15 mg/day) administered orally once daily for at least 24 weeks.

Route of Administration: Oral

In Vitro Use Guide

1 nM omigapil (CGP 3466 protects) PAJU cells from toxicity mediated by GAPDH overexpression.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:09:28 GMT 2025` Edited by `admin` on `Mon Mar 31 18:09:28 GMT 2025`
Record UNII	3Q69BFZ4OP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CGP-3466B

Preferred Name

English

OMIGAPIL MALEATE

Common Name

English

TCH-346

Code

English

DIBENZO(B,F)OXEPIN-10-YLMETHYL-METHYL-PROP-2-YNYL-AMINE MALEATE

Systematic Name

English

N-(DIBENZ(B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-(2-PROPYNYL)AMINE MONOMALEIC ACID SALT

Common Name

English

CGP 3466B

Common Name

English

TCH346

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/1/08/544